Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $129.4 million.

  • Compass Therapeutics' Cash from Financing Activities rose 646815000.0% to $129.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $128.5 million, marking a year-over-year increase of 64361.47%. This contributed to the annual value of $17.3 million for FY2024, which is 49073.25% up from last year.
  • According to the latest figures from Q3 2025, Compass Therapeutics' Cash from Financing Activities is $129.4 million, which was up 646815000.0% from -$815000.0 recorded in Q1 2025.
  • Compass Therapeutics' 5-year Cash from Financing Activities high stood at $129.4 million for Q3 2025, and its period low was -$815000.0 during Q1 2025.
  • For the 3-year period, Compass Therapeutics' Cash from Financing Activities averaged around $14.9 million, with its median value being $11000.0 (2023).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 10952.38% in 2024, then soared by 646815000.0% in 2025.
  • Over the past 3 years, Compass Therapeutics' Cash from Financing Activities (Quarter) stood at -$158000.0 in 2023, then soared by 40.51% to -$94000.0 in 2024, then soared by 137718.09% to $129.4 million in 2025.
  • Its last three reported values are $129.4 million in Q3 2025, -$815000.0 for Q1 2025, and -$94000.0 during Q4 2024.